<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00006457</url>
  </required_header>
  <id_info>
    <org_study_id>NCI 00L1</org_study_id>
    <secondary_id>NU-00L1</secondary_id>
    <secondary_id>DUMC-000346-00-2</secondary_id>
    <secondary_id>NCI-P00-0167</secondary_id>
    <nct_id>NCT00006457</nct_id>
  </id_info>
  <brief_title>Oltipraz in the Prevention of Lung Cancer in People Who Smoke</brief_title>
  <official_title>Clinical Phase I Multiple-Dose Safety Research Study of Oltipraz in Smokers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Northwestern University</source>
  <brief_summary>
    <textblock>
      RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the&#xD;
      development of cancer.&#xD;
&#xD;
      PURPOSE: Randomized phase I trial to study the effectiveness of oltipraz in preventing lung&#xD;
      cancer in people who smoke.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the effect of oltipraz on the level of BP-7,8-diol-9,10-epoxide (BPDE) DNA&#xD;
           adducts in the lung lining cells (macrophages and bronchial epithelial cells) of&#xD;
           smokers.&#xD;
&#xD;
        -  Determine the tolerability and toxicity of this treatment regimen in these patients.&#xD;
&#xD;
        -  Determine the effect of this treatment regimen on the level of macromolecule adducts in&#xD;
           the blood (e.g., BPDE DNA, BPDE hemoglobin, and 8-hydroxy-deoxyguanine), oral lining&#xD;
           cells (BPDE DNA), bladder lining cells (4-aminobiphenyl DNA), and lung macrophages&#xD;
           (8-hydroxy-deoxyguanine) in these patients.&#xD;
&#xD;
        -  Determine the effect of this treatment regimen on the change (decrease) in activation of&#xD;
           NNK as measured by change (increase) in urinary NNAL plus NNAL glucuronide in these&#xD;
           patients.&#xD;
&#xD;
        -  Determine the effect of this treatment regimen on the oxidative state,&#xD;
           glutathione-S-transferase activity, and superoxide dismutase 3 and phase II enzymes in&#xD;
           the lungs and blood of these patients.&#xD;
&#xD;
        -  Compare the changes in oxidative state and phase II enzymes with changes in adduct&#xD;
           levels in the lungs and blood of these patients.&#xD;
&#xD;
        -  Determine the correlation between oltipraz-induced changes in phase II enzymes and&#xD;
           adduct formation with genotypic variation in glutathione-S-transferase isozymes in these&#xD;
           patients.&#xD;
&#xD;
        -  Compare the response to this treatment regimen in terms of oxidative state, phase II&#xD;
           enzymes, and adduct formation in the lungs vs the blood in these patients.&#xD;
&#xD;
      OUTLINE: This is a randomized, double-blind, multicenter study. Patients are stratified&#xD;
      according to participating center. Patients are randomized to one of three treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive an oral placebo weekly.&#xD;
&#xD;
        -  Arm II: Patients receive low-dose oral oltipraz weekly.&#xD;
&#xD;
        -  Arm III: Patients receive high-dose oral oltipraz weekly. Treatment continues for 12&#xD;
           weeks in the absence of unacceptable toxicity.&#xD;
&#xD;
      Patients are followed at 4 weeks.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 66 patients (22 per treatment arm) will be accrued for this&#xD;
      study within 21 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2000</start_date>
  <completion_date type="Actual">April 2004</completion_date>
  <primary_completion_date type="Actual">April 2004</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <condition>Lung Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oltipraz</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Current cigarette smokers&#xD;
&#xD;
               -  At least 20 cigarettes a day&#xD;
&#xD;
               -  No variation of more than 10 in the number of cigarettes smoked per day within&#xD;
                  the past 3 months&#xD;
&#xD;
               -  At least 10 years of smoking any amount&#xD;
&#xD;
               -  Failed to stop smoking after at least one attempt to quit within the last 3 years&#xD;
&#xD;
          -  Prior stage I non-small cell lung cancer allowed if surgically resected with at least&#xD;
             a lobectomy&#xD;
&#xD;
          -  No concurrent evidence of lung cancer&#xD;
&#xD;
          -  Willing to undergo 2 bronchoscopies&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  CBC normal&#xD;
&#xD;
          -  Hemostasis normal&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  PT and PTT normal&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Blood chemistries normal&#xD;
&#xD;
          -  Nonfasting glucose no greater than 200 mg/dL&#xD;
&#xD;
          -  No active renal disease&#xD;
&#xD;
          -  No urinary tract infection by urinalysis (trace protein allowed)&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  EKG normal&#xD;
&#xD;
          -  No coronary artery disease requiring continuous medication&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  Chest radiograph normal (postsurgical changes allowed)&#xD;
&#xD;
          -  No acute or significant chronic abnormality&#xD;
&#xD;
          -  FEV1 greater than 1.8 L or 75% predicted&#xD;
&#xD;
          -  No chronic obstructive pulmonary disease requiring continuous medication&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No known hypersensitivity or prior adverse reaction to oltipraz&#xD;
&#xD;
          -  No inmates or prisoners&#xD;
&#xD;
          -  No medical or psychological condition that would preclude study (e.g., acute&#xD;
             psychosis)&#xD;
&#xD;
          -  No prior malignancy except nonmelanomatous skin cancer, cervical dysplasia, or&#xD;
             curatively treated stage I or II cancer of the head and neck&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 6 months after study&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  At least 3 months since prior potential chemoprevention agent (e.g., oltipraz,&#xD;
             retinoids, or acetylcysteine)&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raymond C. Bergan, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Robert H. Lurie Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Robert H. Lurie Comprehensive Cancer Center, Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611-3013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Comprehensive Cancer Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <study_first_submitted>November 6, 2000</study_first_submitted>
  <study_first_submitted_qc>May 29, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 30, 2003</study_first_posted>
  <last_update_submitted>June 7, 2012</last_update_submitted>
  <last_update_submitted_qc>June 7, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 11, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>non-small cell lung cancer</keyword>
  <keyword>small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oltipraz</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

